反应详情

温度

40 °C

To a solution of benzyl 4-(4-((2-methyl-5-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-2H-1,2,4-triazol-3-yl)methyl)pyridin-2-yl)piperazine-1-carboxylate (200 mg, 0.30 mmol) in AcOH (1 mL), HBr (2 mL, 48% in H2O) was added at RT. The mixture was stirred at 40° C. for 1 h, and then concentrated to give the crude product, which was purified by pre-HPLC (Mobile phase: A=0.01% HCOOH/H2O, B=MeCN; Gradient: B=60%-95% in 18 min; Column: XBridge (C18, 5 um, 30 mm*150 mm) to afford compound 5-(1-methyl-5-(2-(piperazin-1-yl)pyridin-4-yl)methyl)-1H-1,2,4-triazol-3-yl)-3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazole formate salt as a white solid (120 mg, 61%). MS (ES+) C22H21F3N8O2 requires: 486, found: 487[M+H]+; 1H NMR (500 MHz, DMSO-d6) δ ppm 8.32 (bs, 1H), 8.22 (d, J=8.5 Hz, 2H), 8.08 (d, J=5.5 Hz, 1H), 7.60 (d, J=8.5 Hz, 2H), 6.81 (s, 1H), 6.58 (d, J=5.5 Hz, 1H), 4.27 (s, 2H), 4.00 (s, 3H), 3.6-3.48 (m, 4H), 2.99-2.85 (m, 4H).

1. concentrationconcentrated
2. customto give the crude product, which
3. customwas purified by pre-HPLC (Mobile phase
4. waitGradient: B=60%-95% in 18 min